Clinical evaluation and treatment of specific, documented deficiencies and modifiable biological factors that may be limiting physical function, exercise capacity, recovery, or body composition in symptomatic patients.
Evidence-Based Medical Evaluation for Physical Performance, Recovery, and Body Composition
Clinical evaluation and treatment of specific, documented deficiencies and modifiable biological factors that may be limiting physical function, exercise capacity, recovery, or body composition in symptomatic patients.
This content is for educational purposes only. It does not replace an in-person or telehealth consultation with a licensed clinician, and does not constitute medical advice or a treatment plan. All treatment decisions — including the use of hormones, peptides, supplements, or other agents — require individual clinical evaluation, laboratory confirmation, and licensed physician oversight. Do not self-administer any medication or compound based on information in this article.
Evidence-based performance medicine is the clinical evaluation and treatment of specific, documented deficiencies and modifiable biological factors that may be limiting physical function, exercise capacity, recovery, or body composition in symptomatic patients. It is not a system for pushing performance beyond normal physiological limits. It is not a substitute for appropriate training, nutrition, or sleep. And it is not a reason to initiate hormone therapy or other interventions in healthy adults without clear clinical indication.
At Advanced Vitality Group, every treatment decision requires individual assessment, laboratory confirmation, and licensed physician oversight. The distinction between treating a documented deficiency and attempting to exceed normal physiology matters enormously — clinically, ethically, and legally. This article explains what we evaluate, what we treat, and what we do not do.
What Can Limit Physical Performance, Recovery, and Body Composition
Many patients presenting with poor recovery, reduced exercise capacity, or unfavorable body composition changes have at least one correctable biological contributing factor that standard medical care has not identified. The most clinically relevant categories:
| Factor | What Low or Abnormal Values May Suggest | When Medical Evaluation May Be Appropriate |
|---|---|---|
| Testosterone (men) | Symptoms: low libido, fatigue, reduced muscle mass, mood changes, decreased morning erections. Labs: repeatedly confirmed low testosterone | When symptoms are consistent with hypogonadism AND testosterone is unequivocally and consistently low on repeated testing. Not indicated for “low-normal” values without symptoms. |
| Thyroid function (Free T3, Free T4, TSH) | Symptoms: fatigue, cold intolerance, weight gain, cognitive slowing, reduced exercise tolerance. Labs: abnormal thyroid panel | When thyroid assessment, including free hormone levels when clinically indicated, confirms dysfunction. Individualized evaluation per ATA guidelines. |
| Iron / Ferritin | Symptoms: exercise-related fatigue, poor endurance, reduced aerobic capacity. Labs: low ferritin with or without anemia | When ferritin is below clinically relevant thresholds and symptoms are consistent. Performance-context thresholds may differ from standard deficiency cutoffs — requires clinical interpretation. |
| Vitamin D (25-OH) | Symptoms: muscle weakness, fatigue, bone pain. Labs: deficiency (< 20 ng/mL) or insufficiency (20–29 ng/mL) | When deficiency or insufficiency is confirmed. Supplementation to correct deficiency has well-established evidence. Individual targets depend on baseline, symptoms, and comorbidities. |
| Fasting insulin / HOMA-IR | Symptoms: fatigue, poor body composition, energy instability. Labs: elevated fasting insulin indicating insulin resistance | When insulin resistance is documented. Impairs glucose utilization in muscle, reduces anabolic response to training and protein. |
| Magnesium (RBC) | Symptoms: muscle cramps, fatigue, impaired sleep, poor recovery. Labs: below reference range | When deficiency is confirmed. Magnesium is required for ATP synthesis, muscle contraction, and neuromuscular function. |
Note: These are not universal “performance optimization targets.” They are potential findings that may warrant clinical evaluation and individualized treatment decisions based on symptoms, comorbidities, risks, and goals.
Why Hormones Matter — and Where the Limits Are
Testosterone: When Evaluation and Treatment May Be Appropriate
Testosterone plays important roles in muscle protein synthesis, bone density, red blood cell production, fat metabolism, and recovery. Testosterone therapy — when appropriately indicated — has demonstrated meaningful improvements in lean mass, physical function, and bone mineral density in multiple randomized controlled trials, including the Testosterone Trials (Snyder PJ et al., NEJM, 2016).
However, testosterone therapy is not a general performance tool. The Endocrine Society recommends diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone confirmed on repeated testing. The American Urological Association uses a reasonable diagnostic cut-off of below 300 ng/dL in the context of clinical symptoms. Healthy men without symptoms should not be routinely screened and treated when the benefits and risks remain unclear.
At Advanced Vitality Group, testosterone therapy is initiated only for men meeting these criteria. We do not prescribe TRT for “optimization” in men with normal testosterone, for cosmetic body composition goals in the absence of clinical deficiency, or for competitive performance enhancement.
Why “Low-Normal” Is Not Automatically a Diagnosis
Population-based laboratory reference ranges reflect the distribution of values across a large, heterogeneous sample — not what is optimal for a specific individual. A testosterone result in the lower portion of the normal range may be associated with symptoms in some men. However, the decision to treat is not made on laboratory values alone. It requires a full clinical evaluation including symptom burden, medical history, risks, patient goals, and informed consent regarding benefits and uncertainties. This nuanced, individualized approach is what distinguishes evidence-based medicine from hormone optimization marketing.
IGF-1: A Contextual Marker, Not a Universal Target
IGF-1 is a downstream mediator of growth hormone and plays a role in tissue repair, muscle protein synthesis, and satellite cell activation. IGF-1 levels decline with age and may be associated, in selected patients, with impaired tissue repair and recovery capacity. However, IGF-1 should be interpreted using age-adjusted reference ranges in the context of a full endocrine workup — not as a standalone performance-optimization target. Any decision about GH axis evaluation or treatment requires proper endocrine evaluation.
Metabolic and Nutritional Factors That Affect Training Outcomes
Several nutritional and metabolic factors have well-documented effects on exercise capacity, body composition, and recovery, and have clear evidence-based treatment protocols when deficiency or dysfunction is confirmed:
Iron deficiency (with or without anemia)
Impairs mitochondrial electron transport and oxygen delivery. A randomized controlled trial (Hinton PS et al., Journal of Nutrition, 2000) demonstrated measurable improvements in endurance performance with iron supplementation in iron-depleted but non-anemic women. Performance-relevant ferritin thresholds may be higher than standard deficiency cutoffs; clinical context determines the treatment decision.
Vitamin D deficiency
Vitamin D receptors are expressed in skeletal muscle and regulate muscle function. Deficiency (< 20 ng/mL) is associated with muscle weakness and impaired neuromuscular performance. Supplementation to correct documented deficiency is well-supported by evidence. Individual targets should be determined in clinical context, not applied as universal performance targets.
Insulin resistance
Impairs glucose uptake in muscle during and after exercise, reduces the anabolic response to protein feeding, and is associated with unfavorable body composition changes. Lifestyle interventions — diet, exercise, sleep — are first-line; pharmacological options may be appropriate in selected patients with confirmed insulin resistance.
Magnesium deficiency
Magnesium is a required cofactor for ATP synthesis, neuromuscular function, and protein synthesis. Deficiency is more common than clinical testing frequently identifies. RBC magnesium is a more sensitive marker than serum magnesium.
What a Medical Evaluation May Include
A performance and recovery evaluation at Advanced Vitality Group typically includes a comprehensive laboratory panel covering:
Hormonal
Total and free testosterone, SHBG, LH, FSH, DHEA-S, thyroid panel (TSH, Free T3, Free T4), cortisol, IGF-1 (where GH axis evaluation is clinically indicated)
Metabolic
Fasting insulin, fasting glucose, HbA1c, HOMA-IR, comprehensive lipid panel with ApoB, liver and kidney function
Hematological
Complete blood count, ferritin, transferrin saturation, B12, folate
Inflammatory
hs-CRP, IL-6 — elevated systemic inflammation impairs recovery and contributes to tissue degradation
Nutritional
Vitamin D (25-OH), magnesium (RBC), zinc, omega-3 index
These are potential components of an individualized evaluation — not a universal “performance protocol.” Which tests are ordered depends on the individual patient’s symptoms, history, and clinical presentation.
What Treatment May Involve
Lifestyle Foundations — Always First
Regardless of laboratory findings, foundational lifestyle interventions are prioritized: structured exercise (combining aerobic and resistance training), dietary protein optimization (1.6–2.2 g/kg/day for active adults based on meta-analytic evidence), sleep optimization (7–9 hours with attention to sleep quality and sleep disorders), and stress management. These have the strongest and most consistent evidence base for physical function and recovery of any available interventions.
Treatment of Documented Deficiencies
When laboratory testing confirms a specific deficiency or dysfunction, treatment is initiated using evidence-based protocols:
- Testosterone therapy per AUA/Endocrine Society guidelines for confirmed hypogonadism
- Thyroid optimization per ATA guidelines for confirmed dysfunction
- Iron supplementation for confirmed iron deficiency
- Vitamin D supplementation for confirmed deficiency
- Magnesium supplementation where indicated
- Targeted metabolic interventions for confirmed insulin resistance
A Note on Peptides and GH Secretagogues
Some compounds — including ipamorelin, CJC-1295, and other growth hormone secretagogues — are discussed in longevity and performance medicine contexts. It is important to be transparent about their current clinical and regulatory status: the FDA has noted that there are no FDA-approved drug products containing ipamorelin, and has raised safety and compounding concerns regarding its use. These compounds are not established first-line evidence-based therapy for general performance optimization. Any discussion of such compounds requires careful clinical and legal review, full patient disclosure regarding investigational status, and should not be presented as routine care.
How Monitoring Works
All treatment protocols at Advanced Vitality Group are monitored through regular laboratory reassessment — typically at 8–12 weeks after initiation, then every 3–6 months. Monitoring serves two purposes: confirming that interventions are producing the intended biological changes and that they are safe. Adverse effects, symptoms, and lab values are reviewed at each visit, and protocols are adjusted accordingly. No protocol is static.
Key Takeaways
Performance medicine at Advanced Vitality Group addresses documented deficiencies, not general enhancement of normal physiology.
Testosterone therapy requires symptoms consistent with hypogonadism AND confirmed low testosterone on repeated testing per Endocrine Society and AUA guidelines.
“Low-normal” laboratory values are not automatic treatment triggers — clinical evaluation, symptoms, risks, and goals all inform the decision.
Lifestyle medicine (exercise, protein, sleep, stress management) has the strongest evidence base for physical performance and is the foundation of every protocol.
Peptides such as ipamorelin and CJC-1295 are not FDA-approved and are not established first-line therapy — their use requires full clinical and legal review.
All biomarker targets are individualized — they are not universal performance standards applicable to every patient.
Frequently Asked Questions
Scientific References
- Endocrine Society. “Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline.” Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–1744.
- American Urological Association. “Testosterone Deficiency Guideline.” 2022. auanet.org
- Snyder PJ, et al. “Effects of testosterone treatment in older men.” NEJM. 2016;374(7):611–624.
- Hinton PS, et al. “Iron supplementation improves endurance in iron-depleted, nonanemic women.” Journal of Nutrition. 2000;130(3):475–482.
- Garber JR, et al. “Clinical Practice Guidelines for Hypothyroidism in Adults.” Thyroid. 2012;22(12):1200–1235.
- Ceglia L, Harris SS. “Vitamin D and its role in skeletal muscle.” Calcified Tissue International. 2013;92(2):151–162.
- FDA. “October 2024 Meeting of the Pharmacy Compounding Advisory Committee — ipamorelin.” FDA.gov. 2024.
- Lee DH, et al. “Leisure-time physical activity and all-cause mortality.” JAMA Internal Medicine. 2022.
Schedule Your Performance Evaluation
Find out whether correctable deficiencies may be limiting your physical function, recovery, or body composition.